# A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Study · id `cardio:ct-nct01195662` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01195662](<https://clinicaltrials.gov/study/NCT01195662>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01195662

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2245 participants.

## Technical summary

Registry record NCT01195662. Randomized; triple masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-05-23.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2245 participants (enrolled count; ClinicalTrials.gov record NCT01195662, source copy `cardio:ctgov-nct01195662-2016-12-29`, retrieved 2026-10-26)
- Start date: 2010-10 (registry gives no type) (ClinicalTrials.gov record NCT01195662, source copy `cardio:ctgov-nct01195662-2016-12-29`, retrieved 2026-10-26)
- Primary completion: 2013-02 (actual) (ClinicalTrials.gov record NCT01195662, source copy `cardio:ctgov-nct01195662-2016-12-29`, retrieved 2026-10-26)
- Completion: 2013-02 (actual) (ClinicalTrials.gov record NCT01195662, source copy `cardio:ctgov-nct01195662-2016-12-29`, retrieved 2026-10-26)
- Results first posted: 2014-05-23 (ClinicalTrials.gov record NCT01195662, source copy `cardio:ctgov-nct01195662-2016-12-29`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Colombia; Czechia; Denmark; Finland; Germany; Hungary; India; Ireland; Mexico; Poland; Puerto Rico; Romania; United Kingdom (ClinicalTrials.gov record NCT01195662, source copy `cardio:ctgov-nct01195662-2016-12-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01195662-2016-12-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
- Condition: Type 2 Diabetes
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Placebo matching Dapagliflozin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study (`cardio:pubmed-26620248`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: af680eccdffec1f5c68afc37597a97bd87b65c12607aab942242aa77b4bb5d27
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
